A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

Saved in:
Bibliographic Details
Published inLeukemia Vol. 27; no. 3; pp. 725 - 728
Main Authors Ramsingh, G, Westervelt, P, Cashen, A F, Uy, G L, Stockerl-Goldstein, K, Abboud, C N, Bernabe, N, Monahan, R, DiPersio, J F, Vij, R
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.03.2013
Nature Publishing Group
Subjects
631/154/436/1729
631/67/1059/99
692/699/67/1990/283/1897
692/700/1518
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Azacitidine - administration & dosage
Cancer Research
Critical Care Medicine
DNA methylation
Dosage and administration
Dose-Response Relationship, Drug
Drug dosages
Drug therapy
Female
Health aspects
Hematology
Heparan sulfate
Humans
Intensive
Internal Medicine
letter-to-the-editor
Letters to the editor
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Lipoproteins
Lymphoma
Male
Maximum Tolerated Dose
Medical prognosis
Medicine
Medicine & Public Health
Metabolism
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Oncology
Prognosis
Prospective Studies
Remission (Medicine)
Remission Induction
Thalidomide - administration & dosage
Thalidomide - analogs & derivatives
Young Adult
Uruguay
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ObjectType-Feature-3
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2012.214